Wigler I, Peer G, Soferman G, Blum M, Aviram A
Int J Clin Pharmacol Ther Toxicol. 1984 Mar;22(3):162-6.
Based on the vasodilator properties of calcium antagonists, verapamil was recently introduced into the treatment of arterial hypertension. The present study was undertaken to examine the long-term efficacy of this drug in mild and moderate hypertension. In 82 patients with uncontrolled primary or renal hypertension, verapamil was used either alone or in combination with other drugs. In six cases verapamil was withdrawn because of side effects. In the remaining patients a normal average blood pressure was achieved within 7.8 +/- 1.2 weeks of treatment with doses not exceeding 400 mg/day. This effect was maintained for up to 4 years of treatment, although tolerance seemed to develop in about 10% of the patients. In view of this good response and minimal side effects, it is concluded that verapamil is an effective addition to the antihypertensive arsenal.
基于钙拮抗剂的血管舒张特性，维拉帕米最近被引入到动脉高血压的治疗中。本研究旨在检验该药物在轻度和中度高血压中的长期疗效。在82例原发性或肾性高血压控制不佳的患者中，维拉帕米单独使用或与其他药物联合使用。6例患者因副作用停用维拉帕米。在其余患者中，使用剂量不超过400毫克/天，治疗7.8±1.2周内平均血压恢复正常。这种效果在长达4年的治疗中得以维持，尽管约10%的患者似乎出现了耐受性。鉴于这种良好的反应和最小的副作用，可以得出结论，维拉帕米是抗高血压药物库中的一种有效补充药物。
